Table 2. Clinical events and associated safety risks.
| Event* | Associated safety risk | Total N = 1130 |
Treated N = 802 |
Untreated N = 328 |
|---|---|---|---|---|
| Systemic antimicrobial agents | Infection | 944 (83.5) | 772 (96.3) | 172 (52.4) |
| Intravenous antimicrobial agents | Infection | 676 (59.8) | 575 (71.7) | 101 (30.8) |
| Antithrombotic drug prescription | Thrombosis | 700 (61.9) | 607 (75.7) | 93 (28.4) |
| Antithrombotic drugs excluding heparin | Thrombosis | 249 (22.0) | 206 (25.7) | 43 (13.1) |
| Prevention or treatment of TLS/hyperuricemia | TLS/hyperuricemia | 499 (44.2) | 445 (55.5) | 54 (16.5) |
| Rasburicase | TLS | 57 (5.0) | 57 (7.1) | 0 |
| Systemic antifungal agents | Infection | 473 (41.9) | 431 (53.7) | 42 (12.8) |
| Intravenous antifungal agents | Infection | 169 (15.0) | 159 (19.8) | 10 (3.0) |
| Transfusion | Cytopenia | 423 (37.4) | 389 (48.5) | 34 (10.4) |
| Any surgery | Any surgery | 412 (36.5) | 347 (43.3) | 65 (19.8) |
| Emergency admission | Emergency admission | 257 (22.7) | 214 (26.7) | 43 (13.1) |
| In-hospital death | In-hospital death | 240 (21.2) | 187 (23.3) | 53 (16.2) |
| Antiarrhythmic drug prescription | Arrhythmia | 194 (17.2) | 160 (20.0) | 34 (10.4) |
| Steroids for systemic use only (before treatment) | Steroid administration | 180 (15.9) | 180 (22.4) | 0 |
| Diagnosis of ischemic heart disease | Ischemic heart disease | 161 (14.2) | 130 (16.2) | 31 (9.5) |
| Diagnosis of interstitial lung disease | Interstitial lung disease | 80 (7.1) | 62 (7.7) | 18 (5.5) |
| Stem cell transplantation | Transplantation | 68 (6.0) | 68 (8.5) | 0 |
| Diagnosis of intracranial hemorrhage | Intracranial hemorrhage | 12 (1.1) | 8 (1.0) | 4 (1.2) |
| Endoscopic hemostasis for gastrointestinal hemorrhage | Gastrointestinal hemorrhage | 8 (0.7) | 7 (0.9) | 1 (0.3) |
Values are n (%)
*Includes in-hospital death, diagnosis of comorbidities, emergency admission, surgical/diagnostic/medical procedures, and prescription of medications
TLS, tumor lysis syndrome